Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma

Richard S. Finn, Shukui Qin, Masafumi Ikeda, +17

New England Journal of Medicine

TGFβ attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells

Sanjeev Mariathasan, Shannon J. Turley, Dorothee Nickles, +39

Nature

Tumor BiologyCancer ImmunosurveillanceTumour ResponsePd-l1 BlockadeT Cells +10

Long non-coding RNA HOTAIR reprograms chromatin state to promote cancer metastasis

Rajnish A. Gupta, Nilay Shah, Jeewon Kim, +14

Nature

Non-coding Rna HotairChromatinEngineeringChromatin StructureChromatin State +12

Widespread potential for growth-factor-driven resistance to anticancer kinase inhibitors

Timothy R. Wilson, Jane Fridlyand, Yibing Yan, +15

Nature

MedicineKinase InhibitorsAnti-cancer AgentPharmacologyCancer Growth +4

Precision and functional specificity in mRNA decay

Yulei Wang, Chih Long Liu, John D. Storey, +3

Proceedings of the National Academy of Sciences

Genome-wide analysis of mRNA translation profiles in <i>Saccharomyces</i> <i>cerevisiae</i>

Yoav Arava, Yulei Wang, John D. Storey, +3

Proceedings of the National Academy of Sciences

Molecular correlates of clinical response and resistance to atezolizumab in combination with bevacizumab in advanced hepatocellular carcinoma

Andrew X. Zhu, Alexander R. Abbas, Marina Ruiz de Galarreta, +17

Nature Medicine

MedicineImmunologyMolecular CorrelatesPathologyImmune Checkpoint Inhibitor +7

Atezolizumab with or without bevacizumab in unresectable hepatocellular carcinoma (GO30140): an open-label, multicentre, phase 1b study

Michael S. Lee, Baek‐Yeol Ryoo, Chih‐Hung Hsu, +37

The Lancet Oncology

Phase 1BHepatologyMedicineImmunologyPathology +6

Atezolizumab plus bevacizumab versus active surveillance in patients with resected or ablated high-risk hepatocellular carcinoma (IMbrave050): a randomised, open-label, multicentre, phase 3 trial

Shukui Qin, Minshan Chen, Ann‐Lii Cheng, +202

The Lancet

Surgical OncologyHepatologyMedicinePathologyHigh-risk Hepatocellular Carcinoma +6

Distinct molecular mechanisms underlying clinically relevant subtypes of breast cancer: gene expression analyses across three different platforms

Thérese Sørlie, Yulei Wang, Chunlin Xiao, +4

BMC Genomics